-
Evaluation of physician global assessment in patients with b/tsDMARD therapy selection aligned with a molecular signature response classifier: an analysis from The Study to Accelerate Information of Molecular Signatures (AIMS) in Rheumatoid Arthritis -
Galapagos In-licenses Novel Drug Targets for Inflammatory Bowel Disease Discovered by Scipher Medicine’s Spectra™ Platform -
Scipher Medicine Publishes New Data Further Supporting Clinical Utility of PrismRA Blood Test -
Budget Impact and Clinical Outcomes of a Molecular Signature to Inform TNFi Treatment Selection in Commercial Patients with Rheumatoid Arthritis -
Network-based response module comprised of gene expression biomarkers predicts response to infliximab at treatment initiation in ulcerative colitis -
Scipher Medicine to Participate in Truist Securities Life Sciences AI Symposium -
Scipher Medicine Closes $110 Million Financing -
Scipher Medicine to Participate in the 11th Annual SVB Leerink Global Healthcare Conference -
Scipher Medicine Announces Publication of Real-World Study Demonstrating Clinical Utility of PrismRA Blood Test -
Scipher Medicine Leadership to Present at the 40th Annual J.P. Morgan Healthcare Conference -
Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor-ɑ inhibitors: an analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) in rheumatoid arthritis -
Scipher Medicine Appoints Richard Blackburn to its Advisory Board -
Nearly 15% of Prescribing U.S. Rheumatologists Use Scipher Medicine’s PrismRA Blood Test Since Its Launch A Year Ago -
Scipher Medicine Appoints Dr. Michael Elliott to its Science Advisory Board - Guided therapy selection in rheumatoid arthritis using a molecular signature response classifier: an assessment of budget impact and clinical utility